Provectus Biopharmaceuticals, Inc.
PVCT · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $57 | $279 | $14 |
| % Growth | -100% | -79.4% | 1,844.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $57 | -$102 | $14 |
| % Margin | – | 99.2% | -36.6% | 96.8% |
| R&D Expenses | $346 | $867 | $389 | $557 |
| G&A Expenses | $930 | $865 | $863 | $1,724 |
| SG&A Expenses | $930 | $865 | $866 | $1,737 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $13 |
| Other Operating Expenses | $0 | $125 | -$259 | -$493 |
| Operating Expenses | $1,276 | $1,858 | $996 | $1,801 |
| Operating Income | $0 | -$1,801 | -$1,098 | -$2,335 |
| % Margin | – | -3,132.8% | -394.1% | -16,289% |
| Other Income/Exp. Net | $0 | -$51 | -$64 | -$62 |
| Pre-Tax Income | -$1,311 | -$1,852 | -$1,162 | -$2,397 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,311 | -$1,852 | -$1,140 | -$2,397 |
| % Margin | – | -3,222.1% | -409.1% | -16,724.1% |
| EPS | -0.003 | -0.004 | -0.003 | -0.006 |
| % Growth | 27.9% | -59.3% | 52.6% | – |
| EPS Diluted | -0.003 | -0.004 | -0.003 | -0.006 |
| Weighted Avg Shares Out | 420,280 | 420,280 | 420,280 | 419,858 |
| Weighted Avg Shares Out Dil | 420,280 | 420,280 | 420,280 | 419,858 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $48 | $51 | $64 | $62 |
| Depreciation & Amortization | $0 | $0 | $0 | -$7 |
| EBITDA | -$1,263 | -$1,800 | -$1,097 | -$2,334 |
| % Margin | – | -3,132% | -393.7% | -16,285.7% |